Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma
- PMID: 1690599
Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma
Abstract
To evaluate the distribution and density of epidermal growth factor (EGF) receptors (EGF-Rs) on urothelium, immunohistological studies using a monoclonal antibody to the binding portion of the human EGF-R were performed on frozen specimens of normal urothelium (N = 20), urothelium from patients with nonurothelial urological malignancies (N = 15) and inflammatory diseases (N = 8), low grade superficial transitional cell carcinomas (TCC) (N = 13), high grade superficial or invasive TCC (N = 28), and endoscopically normal appearing urothelium from patients with low grade superficial (N = 5) or high grade (N = 21) TCC elsewhere in the bladder (or ipsilateral renal pelvis/ureter). EGF-Rs are found only on the basal layer of epithelial cells (with scattered representation on intermediate cells) in 95% of normal urothelial specimens and 100% of pathological specimens without urothelial malignancy. Alternatively, 92.3% of specimens of low grade superficial TCC and 100% of high grade TCCs had EGF-Rs richly expressed on the superficial as well as the deeper layers of urothelium. This "malignant" distribution of EGF-Rs was also found on all specimens of endoscopically normal appearing urothelium in patients with TCC elsewhere. The density of EGF-Rs correlated closely with tumor grade on both "premalignant" and frankly neoplastic urothelium. We conclude that the expression of EGF-Rs on urothelium favors the interaction of premalignant and malignant tissue with urinary EGF. To determine if altering the physiochemical environment of urine could interfere with this interaction, the effects of pH on the binding of and growth responses to EGF were assessed on four human TCC cell lines. Scatchard plots demonstrated that varying pH from 5.0 to 7.5 did not significantly change the total number of receptors, but EGF-R affinity was reduced approximately 20-fold as pH decreased from 7.5 to 5 in each TCC target. Similarly, significant growth stimulation by EGF at pH 7.5 was abrogated at pH less than or equal to 7.0 while growth rates in the absence of EGF remained unchanged at lower pHs. It thus appears that urinary acidification may hold promise in the management and prevention of recurrent bladder cancer.
Similar articles
-
Expression of the epidermal growth factor receptor family in normal and malignant urothelium.BJU Int. 2005 Jun;95(9):1344-50. doi: 10.1111/j.1464-410X.2005.05497.x. BJU Int. 2005. PMID: 15892828
-
Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.Urol Oncol. 2004 Mar-Apr;22(2):93-101. doi: 10.1016/j.urolonc.2004.01.001. Urol Oncol. 2004. PMID: 15082004
-
Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells.Cancer Res. 1991 Aug 15;51(16):4486-91. Cancer Res. 1991. PMID: 1868471
-
Epidermal growth factor and its receptor: markers of--and targets for--chemoprevention of bladder cancer.J Cell Biochem Suppl. 1992;16I:56-62. doi: 10.1002/jcb.240501312. J Cell Biochem Suppl. 1992. PMID: 1305689 Review.
-
Molecular pathways of urothelial development and bladder tumorigenesis.Urol Oncol. 2010 Jul-Aug;28(4):401-8. doi: 10.1016/j.urolonc.2009.04.019. Urol Oncol. 2010. PMID: 20610278 Review.
Cited by
-
An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer.Cancer Res. 2011 Jun 1;71(11):3812-21. doi: 10.1158/0008-5472.CAN-10-3072. Epub 2011 Apr 21. Cancer Res. 2011. PMID: 21512138 Free PMC article.
-
Peptide growth factors in normal and hypertrophied bladder.World J Urol. 1995;13(6):344-8. doi: 10.1007/BF00191215. World J Urol. 1995. PMID: 9116753 Review.
-
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer.World J Urol. 1997;15(2):112-9. doi: 10.1007/BF02201982. World J Urol. 1997. PMID: 9144901 Review.
-
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery.Cancer Prev Res (Phila). 2025 Jan 6;18(1):31-39. doi: 10.1158/1940-6207.CAPR-24-0194. Cancer Prev Res (Phila). 2025. PMID: 39187984 Free PMC article. Clinical Trial.
-
Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro.J Cancer Res Clin Oncol. 1994;120(9):507-12. doi: 10.1007/BF01221026. J Cancer Res Clin Oncol. 1994. PMID: 8045915 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous